Prognostic Factors of Early Stage Epithelial Ovarian Carcinoma

Shu-Feng Hsieh, Hei-Yu Lau, Hua-Hsi Wu, Heng-Cheng Hsu, Nae-Fang Twu and Wen-Fang Cheng
Additional contact information
Shu-Feng Hsieh: Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei 100, Taiwan
Hei-Yu Lau: Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei 111, Taiwan
Hua-Hsi Wu: Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei 111, Taiwan
Heng-Cheng Hsu: Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei 100, Taiwan
Nae-Fang Twu: Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei 111, Taiwan
Wen-Fang Cheng: Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei 100, Taiwan

IJERPH, 2019, vol. 16, issue 4, 1-12

Abstract: We aimed to determine prognostic factors of early stage (I/II) epithelial ovarian carcinoma (EOC) including clinicopathologic and chemotherapeutic regimens. Four hundred and thirty-seven women who underwent primary staging surgery with adjuvant chemotherapy between January 1, 2000 and December 31, 2010 were retrospectively reviewed and analyzed from two medical centers. The prognostic factors were determined from multivariate survival analyses using Cox regression models. The majority of women were diagnosed with stage Ic (244/437, 55.8%). The histopathologic types were clear cell (37.5%), endometrioid (27.2%), serous (14.0%), and mucinous (13.3%). Fifty-seven percent (249/437) of the women received taxane-based (platinum plus paclitaxel) regimens and 43.0% received non-taxane (platinum plus cyclophosphamide) regimens as frontline adjuvant chemotherapy. Clear cell tumors (adjusted Hazard ratio (aHR) 0.37, 95% confidence interval (CI) 0.21–0.73, p = 0.001) showed better 5-year disease-free survival (DFS) than serous tumors. Women diagnosed at FIGO (International Federation of Gynecology and Obstetrics) stage II (aHR 5.97, 95% CI = 2.47–14.39, p < 0.001), grade 3 tumor without clear cell (aHR 2.28, 95% CI = 1.02–5.07, p = 0.004) and who received 3–5 cycles of non-taxane regimens (aHR 3.29, 95% CI = 1.47–7.34, p = 0.004) had worse 5-year overall survival (OS). Clear cell histology treated with taxane-based regimens showed significantly higher 5-year DFS (91.2% vs. 82.0%, aHR = 0.45, 95% CI = 0.21–0.93, p = 0.043) and 5-year OS (93.5% vs. 79.0%, aHR = 0.30, 95% CI = 0.13–0.70, p = 0.005) than those treated with non-taxane-based regimens. We conclude that stage, tumor grade, and chemotherapeutic regimens/cycles are independent prognostic factors for early stage ovarian cancer.

Keywords: ovarian cancer; platinum; taxane; histologic type; disease-free survival; overall survival (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2019
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.mdpi.com/1660-4601/16/4/637/pdf (application/pdf)
https://www.mdpi.com/1660-4601/16/4/637/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:16:y:2019:i:4:p:637-:d:207938

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().